Professor Matthew Cooper is CEO of Inflazome Ltd. and has an equity interest in the company of which UQ is also a shareholder through its commercialisation company UniQuest Pty. Ltd. Inflazome Ltd. is a company headquartered in Dublin, Ireland that is developing drugs to address clinical unmet needs in inflammatory disease by targeting the inflammasome. Professor Cooper also holds a fractional Professorial Research Fellow appointment at the University of Queensland. The terms of this arrangement have been reviewed and approved by the University of Queensland, in accordance with its conflict of interest policies.

Matt Cooper completed his PhD in Australia in 1995 and then spent 13 years in the UK, first at the University of Cambridge, then in start-ups and biotechnology companies. This involved innovation, fund raising, intellectual property generation, licensing, product development and commercialisation.

He returned to Australia in 2009 as a NHMRC Australia Fellow. He has consulted with Private Equity Investment, Pharmaceutical, Biotechnology and Diagnostics companies, was Managing Director of Cambridge Medical Innovations (part of Alere Inc.) and CSO of Akubio Ltd.He is an inventor and driver of a several antibiotic drug discovery programmes with lead compounds pre-clinical. He is an expert in label-free technologies and their application to drug discovery and development with two books in this field.

He co-founded CO-ADD in 2015.